Autoimmune diseases are a spectrum of conditions in which the immune system mistakenly attacks one’s own body, including systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis. These diseases are among the global burden of diseases affecting over 200 million people worldwide and representing a leading cause of death for women under 65.

Autoimmune diseases are commonly treated by gene therapy and antibody therapy with remarkable success. However, significant financial burdens and poor patient compliance impeded extensive application of these therapies. Therefore, it is of importance to address such unmet medical needs and develop efficacious and cost-effective treatment for patients with autoimmune diseases.

Small-molecule kinase inhibitors exhibit superior target specificity, cellular permeability, patient compliance as well as cost-effectiveness as compared to biologics. SinnoHub is dedicated to developing small-molecule kinase inhibitors in order to alleviate symptoms of autoimmune diseases.